Search

Displaying results 5581 - 5590 of 7181 in total
  1. Drug

    Tomligisiran

    go.drugbank.com/drugs/DB19330
    Investigational

    Tomligisiran is under investigation in clinical trial NCT06537414 (A Study of Sequential Therapy With Daplusiran/tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis

    Synonyms: AMINO-9H-PURIN-9-YL))DA-(5'->5')-CM-GM-CM-UM-GM-UM-AM-GM-(2'-DEOXY-2'-FLUORO)G-(2'-DEOXY-2'-FLUORO)C-(2'-DEOXY-2'-FLUORO)A-UM-AM-AM-AM-UM-UM-GM-GM-UM-AM-(3'->3')-SP-(1'-DE(6-AMINO-9H-PURIN-9-YL))DA), 3'-(O-
  2. Drug

    Daplusiran

    go.drugbank.com/drugs/DB19331
    Investigational

    Daplusiran is under investigation in clinical trial NCT06537414 (A Study of Sequential Therapy With Daplusiran/tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis

  3. Drug

    EB05

    go.drugbank.com/drugs/DB16477
    Investigational

    EB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.

  4. Drug

    Gold

    go.drugbank.com/drugs/DB14154
    Investigational

    Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.

  5. Drug

    Altropane I-123

    go.drugbank.com/drugs/DB15144
    Investigational

    Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

  6. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

  7. Drug

    AEG35156

    go.drugbank.com/drugs/DB06184
    Investigational

    This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. … XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.

  8. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways.

  9. Drug

    Malathion

    go.drugbank.com/drugs/DB00772
    Approved

    Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice. Malathion is an irreversible cholinesterase inhibitor and has low human toxicity.

    Synonyms: O,O-dimethyl S-(1,2-bis(ethoxycarbonyl)ethyl), O,O-dimethyl S-1,2-di(ethoxycarbamyl)ethyl
  10. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. … It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind